Global Dengue Vaccine Market
Dengue Vaccine Market Size And Forecast
According to Verified Market Research, Global Dengue Vaccine Market was valued at USD 279 Million in 2018 and is projected to reach USD 972.3 Million by 2026, growing at a CAGR of 16.8% from 2019 to 2026.
Global Dengue Vaccine Market Outlook
Factors such as the rising prevalence of dengue fever, a growing number of government initiatives, lack of basic amenities in communities, poor environmental management, and unplanned and uncontrolled urbanization are anticipating in fueling the demand for dengue vaccines. Moreover, climate change facilitates increasing transmission of dengue, globalization, and tourism, and population growth is further expected to increase the demand for dengue vaccines. On the other hand, factors such as inadequate cold chain systems for storage of vaccines, stiff competition among existing players to develop a new vaccine, high possibilities of side effect of vaccine, complications, and severity involved in taking wrong medications due to misdiagnosis or incorrect self-diagnosis are might restrict the growth for dengue vaccines.
Global Dengue Vaccine Market Competitive Landscape
The Global Dengue Vaccine Market study report will provide a valuable insight with an emphasis on global market including some of the major players such as GlaxoSmithKline plc, Sanofi Pasteur, Biological E. Limited, Panacea Biotec, Merck & Co., Inc., Takeda Pharmaceutical Company Ltd., Johnson & Johnson, Pfizer, Novartis Pharmaceutical, and Vabiotech Vaccines Center.
Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.